Cleerly® Launches the Cleerly® ISCHEMIA™ for Heart Disease Analysis
Kanesa David — January 10, 2024 — Tech
References: cleerlyhealth & businesswire
Cleerly has officially announced the new Cleerly ISCHEMIA, which supports heart disease patients. Cleerly ISCHEMIA is an automated machine learning-based decision support tool strategically designed to serve as a diagnostic aid for patients undergoing coronary computed tomography angiography (CCTA) analysis using Cleerly Labs software.
“We are pleased to have FDA 510(k) clearance for Cleerly ISCHEMIA and offer the software as part of Cleerly Labs to providers to support their diagnosis of patients across the entire heart disease continuum,” said James K. Min, MD, FACC, FESC, MSCCT, founder and CEO of Cleerly.
Cleerly ISCHEMIA utilizes artificial intelligence capabilities to assess coronary vessel ischemia by analyzing quantitative measures of atherosclerosis, stenosis, and vascular morphology from patients' CCTA images. This functionality helps the detection of likely ischemia associated with coronary artery disease (CAD).
Image Credit: Cleerly
“We are pleased to have FDA 510(k) clearance for Cleerly ISCHEMIA and offer the software as part of Cleerly Labs to providers to support their diagnosis of patients across the entire heart disease continuum,” said James K. Min, MD, FACC, FESC, MSCCT, founder and CEO of Cleerly.
Cleerly ISCHEMIA utilizes artificial intelligence capabilities to assess coronary vessel ischemia by analyzing quantitative measures of atherosclerosis, stenosis, and vascular morphology from patients' CCTA images. This functionality helps the detection of likely ischemia associated with coronary artery disease (CAD).
Image Credit: Cleerly
Trend Themes
1. AI-powered Heart Analyses - AI-powered tools like Cleerly ISCHEMIA are disrupting the field of heart disease analysis by providing diagnostic aid through automated machine learning-based decision support.
2. Quantitative Analysis of Atherosclerosis - The use of quantitative measures in analyzing atherosclerosis is a disruptive innovation opportunity that can enhance the detection of likely ischemia in coronary artery disease patients.
3. Automated Diagnostic Support Tools - Automated diagnostic support tools, such as Cleerly ISCHEMIA, offer a disruptive innovation in the field of coronary computed tomography angiography (CCTA) analysis, providing efficient and accurate diagnostic aid for heart disease patients.
Industry Implications
1. Healthcare Technology - The healthcare technology industry can take advantage of AI-powered tools, like Cleerly ISCHEMIA, to improve the accuracy and efficiency of heart disease analysis.
2. Medical Imaging - The medical imaging industry can benefit from automated machine learning-based decision support tools, such as Cleerly ISCHEMIA, as they enhance the diagnostic capabilities of coronary computed tomography angiography (CCTA) analysis.
3. Cardiology - The cardiology industry can leverage the use of automated diagnostic support tools, like Cleerly ISCHEMIA, to enhance the detection and diagnosis of coronary artery disease in patients undergoing CCTA analysis.
6.6
Score
Popularity
Activity
Freshness
